Since its very beginning Hexacath has made tremendous efforts to set up a robust clinical programme with numerous randomized controlled studies demonstrating each time at 1and 5 year of follow up Titan bioactive stent non-inferiority versus all 3 drug eluting-stents generations reaching the superiority in safety (a composite of cardiac death, AMI and major bleeding). In 2024, Hexacath has gathered more than 50 publications about the Optimax and RayFlow technologies in top ranking Journals such as JACC, JACC CI, JAMA Cardiology, EuroInterventions…   

We challenge the status quo and established therapies. Our technologies are innovative, unique and patented. Our flagship products and technologies have been devised by leading cardiologists and are the results of a tight collaboration between brilliant physicians and the industry. We are focused on technologies that can better serve the patients and the medical community.

Hexacath and collaborators are driven to always deliver higher quality products to customers with the ultimate goal of improving the quality of life of patients with minimally invasive new therapies.

We maintain very high level of controls in every Hexacath plants and we have been successful obtaining the highest demanding certifications and regulations such as CE mark at MDD and MDR levels, FDA registration, ISO Standards 13485.

At Hexacath we have always been committed to minimizing the environmental impact of our business operations. We are already dealing with companies that have set policies with regards to the environment. 100% of all our suppliers in terms of packaging are certified Imprim’Vert. A Corporate Social Responsibility mindset has led the company to re-think its packaging to reduce volumes and minimize the carbon emission during shipping. In short, we have reduced significantly our packaging size by 33% for our coronary medical devices such as stents, PTCA ballloons and microcatheters. We have replaced our packaging material by recyclable cardboard as soon as 2012. We have used thinner paper to print our instruction for use (IFUs) leading to 22% reduction in terms of waste. In addition, we have managed to reduce the number of pages of all our instruction for use by 25%. We believe these steps will contribute to reduce the waste and carbon footprint of our products and will contribute favourably to a better environment.

We are easy to work with and give our customers the access to a wide platform of technologies and modern high-tech equipments in the field orf cardio-vascular therapies. This includes skilled technical (Engineers, pharmacists, clinicians) and customers support (Sales Representatives). Hexacath employees also collaborate across departments, offices locations and various subsidiaries abroad to share best practices to work more efficiently.